Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 251, Issue 1, 2013, Pages 279-284

  Westekemper, Henrike ^a   Freistuehler, Michael ^a   Bornfeld, Norbert ^a   Steuhl, Klaus Peter ^a   Scheulen, Max ^a   Hilger, Ralf A ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cell lines; Chemosensitivity; Conjunctival melanoma; SRB assay

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CLUSIANONE 502; NEMOROSONE; RANPIRNASE; SORAFENIB; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONJUNCTIVA TUMOR; CONJUNCTIVAL MELANOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; IC 50; IN VITRO STUDY; MELANOMA CELL; PRIORITY JOURNAL; RECURRENT CANCER;

ANTINEOPLASTIC AGENTS; BENZOPHENONES; BORONIC ACIDS; CELL PROLIFERATION; CONJUNCTIVAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MELANOMA; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRAZINES; RIBONUCLEASES; TUMOR CELLS, CULTURED;

EID: 84872352766     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-012-2083-8     Document Type: Article

References (38)

1. Demirci H, McCormick S, Finger P (2000) Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: clinical experience with histopathologic observations. Arch Ophthalmol 118(7):885-891
2. Finger P, Czechonska G, Liarikos S (1998) Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol 82:476-479
3. Kurli M, Finger P (2005) Topical mitomycin chemotherapy for conjunctival malignant melanoma and primary acquired melanosis with atypia: 12 years' experience. Graefes Arch Clin Exp Ophthalmol 243(11):1108-1114
4. Folberg R, Mc Lean IW, Zimmermann LE (1985) Malignant melanoma of the conjunctiva. Hum Pathol 16:136-143
5. Seregard S, Kock E (1992) Conjunctival malignant melanoma in Sweden 1969-1991. Acta Ophthalmol Scand 70:289-296
6. Nareyeck G, Wuestemeyer H, von der Haar D, Anastassiou G (2005) Establishment of two cell lines derived from conjunctival melanomas. Exp Eye Res 81:361-362
7. Westekemper H, Freistuehler M, Anastassiou G, Nareyeck G, Bornfeld N, Steuhl K, Scheulen M, Hilger R (2012) Chemosensitivity of conjunctival melanoma cell lines to single chemotherapeutic agents and combinations. Br J Ophthalmol 96(4):591-596
8. Adams J, Palombella V, Sausville E, Johnson J, Destree A, Lazarus D, Maas J, Pien C, Prakash S, Elliott P (1999) Proteasome Inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622
9. Ludwig H, Khayat D, Giaccone G, Facon T (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104:1794-1807
10. Montagut C, Rovira A, Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8(5):313-317
11. Simons S, Scheulen M, Jaehde U (2006) Bortezomib. Dtsch Med Wochenschr 131(5):214-218
12. Diaz-Carballo D, Seeber S, Strumberg D, Hilger RA (2003) Novel antitumoral compound isolated from Clusia rosea. Int J Clin Pharmacol Ther 41(12):622-623
13. Diaz-Carballo D, Malak S, Freistuhler M, Elmaagacli A, Bardenheuer W, Reusch HP (2008) Nemorosone blocks proliferation and induces apoptosis in leukemia cells. Int J Clin Pharmacol Ther 46(8):428-439
14. Holtrup F, Bauer A, Fellenberg K, Hilger RA, Wink M, Hoheisel JD (2011) Microarray analysis of nemorosone-induced cytotoxic effects on pancreatic cancer cells reveals activation of the unfolded protein response (UPR). Br J Pharmacol 162(5):1045-1059
15. Lee I (2008) Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. Expert Opin Biol Ther 8(6):813-827
16. Haigis M, Kurten E, Raines R (2003) Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res 31(3):1024-1032
17. Wilhelm S, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post L, Bollag G, Trail P (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109
18. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm S, Santoro M (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98(5):326-334
19. Westekemper H, Freistuehler M, Anastassiou G, Nareyeck G, Zeschnigk M, Bornfeld N, Steuhl K, Scheulen M, Hilger R (2011) Chemosensitivity of conjunctival melanoma cell lines to chemotherapeutic agents. Int J Clin Pharmacol Ther 48(1):78-80
20. Tschentscher F, Prescher G, Zeschnigk M, Horsthemke B, Lohmann DR (2000) Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet 122(1):13-17
21. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren J, Bokesch H, Kenney S, Boyd M (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82(13):1107-1112
22. Wang W, Abbruzzese J, Evans D, Larry L, Cleary K, Chiao P (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5:119-127
23. Duffey D, Chen Z, Dong G, Ondrey F, Nejad-Sattari M, Dong G, Van Waes C (1999) Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 59:3468-3474
24. Shattuck-Brandt R, Richmond A (1997) Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res 57:3032-3039
25. Dhawan P, Richmond A (2002) A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells. J Biol Chem 277:7920-7928
26. Yang J, Richmond A (2001) Constitutive kappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 61:4901-4909
27. Nyormoi O, Bar-Eli M (2003) Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 20:251-263
28. Ivanov V, Bhoumik A, Ronai Z (2003) Death receptors and melanoma resistance to apoptosis. Oncogene 22:3152-3161
29. Amiri K, Horton L, LaFleur B, Sosman J, Richmond A (2004) Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 64:4912-4918
30. Arnold U, Schulenburg C, Schmidt D, Ulbrich-Hofmann R (2006) Contribution of structural peculiarities of onconase to its high stability and folding kinetics. Biochemistry 45:3580-3587
31. Leland P, Schultz L, Kim B, Raines R (1998) Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci U S A 95:10407-10412
32. Arnold U, Ulbrich-Hofmann R (2006) Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 28:1615-1622
33. Benito A, Ribo M, Vilanova M (2005) On the track of antitumour ribonucleases. Mol Biosyst 1:294-302
34. Pavlakis N, Vogelzang N (2006) Ranpirnase-an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther 6:391-399
35. Egberts F, Kahler K, Livingstone E, Hauschild A (2008) Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie 31(7):398-403
36. McDermott D, Sosman J, Gonzalez R, Hodi F, Linette G, Richards J, Jakub J, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White J, Xia H, Patel K, Hersh E (2008) Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 1(26):2178-2185
37. Panka DJ, Wang W, Atkins MB, Mier JW (2006) The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66(3):1611-1619
38. Fecher L, Amaravadi R, Flaherty K (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20(2):183-189